Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 386

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 386
---
841 |      419 |                       22,629 |

(a) Comprises the other intangible assets of Opella, now reclassified to Assets held for sale at December 31, 2024 in accordance with IFRS 5 (see note D.1.).

(b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets (other than

Opella assets) as Assets held for sale .

(c) The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during

the period (see Note D.1.) .

(d) See Note D.5.

| F-42 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

(e) The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of € 226million in 2022 (see Note C.1.) . (f) This line mainly comprises: In 2023: – the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus (nirsevimab) (see Note C.2.); – an upfront payment of $ 500million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co- commercialization of TEV’574;and – an upfront payment of $ 175million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli. In 2024: – an upfront payment of $ 500million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and – an upfront payment of $ 300million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and commercialization rights to aficamten in China. “Products, trademarks and other rights” mainly comprise: • “marketed products”, with a carrying amount of € 12.7billion as of December 31, 2024 (versus € 16.6billion as of December 31, 2023 and € 12.7billion